AGÕæÈ˹ٷ½

STOCK TITAN

[8-K] Privia Health Group, Inc. Reports Material Event

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
8-K
Rhea-AI Filing Summary

Privia Health Group (PRVA) filed an 8-K (Item 5.02) announcing a governance change. Effective July 15, 2025, the Board will expand from nine to ten seats and elect Lance Berberian as a Class III independent director. He will also join the Audit Committee and meets Nasdaq’s heightened independence, financial sophistication and literacy standards.

Under the company’s Non-Employee Director Compensation Program, Mr. Berberian will receive a standard annual cash retainer (amount not disclosed) and an equity award of restricted stock units valued at $200,000, pro-rated for his first partial term. The company states there are no related-party transactions and no special arrangements behind his selection. A confirming press release (Exhibit 99.1) was issued on July 8, 2025.

The filing is purely a corporate governance update; no operational, financial or strategic guidance is provided. While the addition of an independent, audit-qualified director should strengthen oversight and align with best-practice governance, the event is unlikely to have a material near-term financial impact.

Privia Health Group (PRVA) ha presentato un modulo 8-K (Voce 5.02) annunciando una modifica nella governance. A partire dal 15 luglio 2025, il Consiglio di Amministrazione passerà da nove a dieci membri ed eleggerà Lance Berberian come amministratore indipendente di Classe III. Egli entrerà anche a far parte del Comitato di Revisione e soddisfa gli elevati standard di indipendenza, competenza finanziaria e alfabetizzazione richiesti da Nasdaq.

Secondo il Programma di Compenso per Amministratori Non Dipendenti della società, il signor Berberian riceverà un compenso annuale in contanti standard (importo non divulgato) e un premio in azioni vincolate (restricted stock units) del valore di 200.000 $, proporzionato al suo primo mandato parziale. La società dichiara che non vi sono transazioni con parti correlate né accordi speciali alla base della sua nomina. Un comunicato stampa confermativo (Allegato 99.1) è stato pubblicato l'8 luglio 2025.

La comunicazione rappresenta un aggiornamento esclusivamente di governance aziendale; non sono forniti indicazioni operative, finanziarie o strategiche. Sebbene l'inserimento di un amministratore indipendente qualificato per la revisione contabile dovrebbe rafforzare il controllo e allinearsi alle migliori pratiche di governance, l'evento difficilmente avrà un impatto finanziario rilevante nel breve termine.

Privia Health Group (PRVA) presentó un formulario 8-K (Artículo 5.02) anunciando un cambio en la gobernanza. A partir del 15 de julio de 2025, la Junta se ampliará de nueve a diez miembros y elegirá a Lance Berberian como director independiente de Clase III. También se unirá al Comité de Auditoría y cumple con los estrictos requisitos de independencia, sofisticación financiera y alfabetización de Nasdaq.

Bajo el Programa de Compensación para Directores No Empleados de la empresa, el Sr. Berberian recibirá una retención anual estándar en efectivo (monto no revelado) y una concesión de acciones restringidas valorada en 200,000 $, prorrateada para su primer mandato parcial. La empresa declara que no existen transacciones con partes relacionadas ni acuerdos especiales detrás de su selección. Un comunicado de prensa confirmatorio (Exhibición 99.1) fue emitido el 8 de julio de 2025.

La presentación es únicamente una actualización de gobernanza corporativa; no se proporciona orientación operativa, financiera ni estratégica. Aunque la incorporación de un director independiente cualificado en auditoría debería fortalecer la supervisión y alinearse con las mejores prácticas de gobernanza, es poco probable que el evento tenga un impacto financiero material a corto plazo.

Privia Health Group (PRVA)ëŠ� 8-K ë³´ê³ ì„�(Item 5.02)ë¥� 제출하여 거버넌스 ë³€ê²½ì„ ë°œí‘œí–ˆìŠµë‹ˆë‹¤. 2025ë…� 7ì›� 15ì¼ë¶€í„� ì´ì‚¬íšŒëŠ” 9명ì—ì„� 10명으ë¡� 확대ë˜ë©°, Lance Berberianì� Class III ë…립 ì´ì‚¬ë¡� ì„ ìž„í•� 예정입니ë‹�. 그는 ê°ì‚¬ìœ„ì›íšŒì—ë� 합류하며, ë‚˜ìŠ¤ë‹¥ì˜ ê°•í™”ë� ë…립ì„�, 금융 전문ì„� ë°� ì´í•´ë � 기준ì� 충족합니ë‹�.

회사ì� 비임ì›� ì´ì‚¬ ë³´ìƒ í”„ë¡œê·¸ëž¨ì—� ë”°ë¼ Berberian 씨는 표준 ì—°ê°„ 현금 보수(금액 비공ê°�)와 ì²� 임기 ì¼ë¶€ì—� 대í•� 비례 ë°°ë¶„ë� 20ë§� 달러 ìƒë‹¹ì� 제한 ì£¼ì‹ ë‹¨ìœ„(RSU) ë³´ìƒì� 받습니다. 회사ëŠ� ê´€ë � 당사ìž� 거래ë‚� 특별í•� í•©ì˜ê°€ ì—†ìŒì� 명시했습니다. 확ì¸ìš� ë³´ë„ìžë£Œ(첨부ìžë£Œ 99.1)ëŠ� 2025ë…� 7ì›� 8ì¼ì— 발표ë˜ì—ˆìŠµë‹ˆë‹�.

ì´ë²ˆ ë³´ê³ ëŠ� 순전íž� 기업 거버넌스 ì—…ë°ì´íЏì´ë©°, ìš´ì˜, 재무 ë˜ëŠ” ì „ëžµì � ì§€ì¹¨ì€ ì œê³µë˜ì§€ 않았습니ë‹�. ë…립ì ì´ê³� ê°ì‚¬ ìžê²©ì� 갖춘 ì´ì‚¬ì� 추가ëŠ� ê°ë…ì� 강화하고 최선ì� 거버넌스 관행과 ì¼ì¹˜í•˜ì§€ë§�, 단기ì ìœ¼ë¡� 재무ì—� 중대í•� ì˜í–¥ì� 미칠 ê°€ëŠ¥ì„±ì€ ë‚®ìŠµë‹ˆë‹¤.

Privia Health Group (PRVA) a déposé un formulaire 8-K (point 5.02) annonçant un changement de gouvernance. À compter du 15 juillet 2025, le conseil d'administration passera de neuf à dix membres et élira Lance Berberian en tant qu'administrateur indépendant de classe III. Il rejoindra également le comité d'audit et répond aux exigences accrues de Nasdaq en matière d'indépendance, de sophistication financière et de maîtrise des connaissances financières.

Dans le cadre du programme de rémunération des administrateurs non salariés de la société, M. Berberian recevra une rémunération annuelle standard en espèces (montant non divulgué) ainsi qu'une attribution d'unités d'actions restreintes d'une valeur de 200 000 $, au prorata de son premier mandat partiel. La société déclare qu'il n'y a aucune transaction avec des parties liées ni d'accords particuliers liés à sa nomination. Un communiqué de presse confirmatif (Exhibit 99.1) a été publié le 8 juillet 2025.

Le dépôt constitue uniquement une mise à jour de la gouvernance d'entreprise ; aucune orientation opérationnelle, financière ou stratégique n'est fournie. Bien que l'ajout d'un administrateur indépendant qualifié en audit devrait renforcer la surveillance et s'aligner sur les meilleures pratiques de gouvernance, cet événement est peu susceptible d'avoir un impact financier significatif à court terme.

Privia Health Group (PRVA) hat ein 8-K Formular (Punkt 5.02) eingereicht, in dem eine Änderung der Unternehmensführung angekündigt wird. Ab dem 15. Juli 2025 wird der Vorstand von neun auf zehn Mitglieder erweitert und Lance Berberian als unabhängiges Direktor der Klasse III gewählt. Er wird außerdem dem Prüfungsausschuss beitreten und erfüllt die verschärften Anforderungen von Nasdaq an Unabhängigkeit, finanzielle Fachkenntnis und Finanzkompetenz.

Im Rahmen des Vergütungsprogramms für nicht angestellte Direktoren erhält Herr Berberian eine standardmäßige jährliche Barvergütung (Höhe nicht veröffentlicht) sowie eine Aktienzuteilung in Form von Restricted Stock Units im Wert von 200.000 $, anteilig für seine erste Teilamtszeit. Das Unternehmen gibt an, dass keine Transaktionen mit verbundenen Parteien oder besondere Absprachen seiner Ernennung zugrunde liegen. Eine bestätigende Pressemitteilung (Anlage 99.1) wurde am 8. Juli 2025 veröffentlicht.

Die Einreichung stellt ausschließlich ein Update der Unternehmensführung dar; es werden keine operativen, finanziellen oder strategischen Prognosen gegeben. Obwohl die Ernennung eines unabhängigen, prüfungserfahrenen Direktors die Aufsicht stärken und den Best-Practice-Governance-Standards entsprechen sollte, wird das Ereignis voraussichtlich keine wesentlichen kurzfristigen finanziellen Auswirkungen haben.

Positive
  • Board expansion with an independent, financially literate director improves oversight and meets Nasdaq audit committee standards.
  • $200,000 equity-based RSU grant aligns the new director’s incentives with shareholder value.
Negative
  • None.

Insights

TL;DR: Board expands; independent, audit-savvy director added—good governance signal, financially immaterial.

The move increases the Board from nine to ten members and installs Lance Berberian on the Audit Committee. His independence and financial literacy satisfy Nasdaq requirements, reinforcing oversight and reducing governance-risk premiums. Compensation terms follow the standing plan, aligning director interests through a $200k RSU grant. No red flags appear (no related-party transactions, standard pay). Overall impact: governance positive, but limited effect on valuation or cash flow.

TL;DR: Routine governance update; strengthens audit oversight, but offers no new earnings or strategy data.

Investors gain assurance that PRVA maintains compliance with listing standards by adding an independent audit committee member. However, the filing contains no revenue, margin or outlook information, so there is minimal basis for revising forecasts. Market reaction should be muted unless Mr. Berberian’s future contributions yield strategic shifts, which the document does not address.

Privia Health Group (PRVA) ha presentato un modulo 8-K (Voce 5.02) annunciando una modifica nella governance. A partire dal 15 luglio 2025, il Consiglio di Amministrazione passerà da nove a dieci membri ed eleggerà Lance Berberian come amministratore indipendente di Classe III. Egli entrerà anche a far parte del Comitato di Revisione e soddisfa gli elevati standard di indipendenza, competenza finanziaria e alfabetizzazione richiesti da Nasdaq.

Secondo il Programma di Compenso per Amministratori Non Dipendenti della società, il signor Berberian riceverà un compenso annuale in contanti standard (importo non divulgato) e un premio in azioni vincolate (restricted stock units) del valore di 200.000 $, proporzionato al suo primo mandato parziale. La società dichiara che non vi sono transazioni con parti correlate né accordi speciali alla base della sua nomina. Un comunicato stampa confermativo (Allegato 99.1) è stato pubblicato l'8 luglio 2025.

La comunicazione rappresenta un aggiornamento esclusivamente di governance aziendale; non sono forniti indicazioni operative, finanziarie o strategiche. Sebbene l'inserimento di un amministratore indipendente qualificato per la revisione contabile dovrebbe rafforzare il controllo e allinearsi alle migliori pratiche di governance, l'evento difficilmente avrà un impatto finanziario rilevante nel breve termine.

Privia Health Group (PRVA) presentó un formulario 8-K (Artículo 5.02) anunciando un cambio en la gobernanza. A partir del 15 de julio de 2025, la Junta se ampliará de nueve a diez miembros y elegirá a Lance Berberian como director independiente de Clase III. También se unirá al Comité de Auditoría y cumple con los estrictos requisitos de independencia, sofisticación financiera y alfabetización de Nasdaq.

Bajo el Programa de Compensación para Directores No Empleados de la empresa, el Sr. Berberian recibirá una retención anual estándar en efectivo (monto no revelado) y una concesión de acciones restringidas valorada en 200,000 $, prorrateada para su primer mandato parcial. La empresa declara que no existen transacciones con partes relacionadas ni acuerdos especiales detrás de su selección. Un comunicado de prensa confirmatorio (Exhibición 99.1) fue emitido el 8 de julio de 2025.

La presentación es únicamente una actualización de gobernanza corporativa; no se proporciona orientación operativa, financiera ni estratégica. Aunque la incorporación de un director independiente cualificado en auditoría debería fortalecer la supervisión y alinearse con las mejores prácticas de gobernanza, es poco probable que el evento tenga un impacto financiero material a corto plazo.

Privia Health Group (PRVA)ëŠ� 8-K ë³´ê³ ì„�(Item 5.02)ë¥� 제출하여 거버넌스 ë³€ê²½ì„ ë°œí‘œí–ˆìŠµë‹ˆë‹¤. 2025ë…� 7ì›� 15ì¼ë¶€í„� ì´ì‚¬íšŒëŠ” 9명ì—ì„� 10명으ë¡� 확대ë˜ë©°, Lance Berberianì� Class III ë…립 ì´ì‚¬ë¡� ì„ ìž„í•� 예정입니ë‹�. 그는 ê°ì‚¬ìœ„ì›íšŒì—ë� 합류하며, ë‚˜ìŠ¤ë‹¥ì˜ ê°•í™”ë� ë…립ì„�, 금융 전문ì„� ë°� ì´í•´ë � 기준ì� 충족합니ë‹�.

회사ì� 비임ì›� ì´ì‚¬ ë³´ìƒ í”„ë¡œê·¸ëž¨ì—� ë”°ë¼ Berberian 씨는 표준 ì—°ê°„ 현금 보수(금액 비공ê°�)와 ì²� 임기 ì¼ë¶€ì—� 대í•� 비례 ë°°ë¶„ë� 20ë§� 달러 ìƒë‹¹ì� 제한 ì£¼ì‹ ë‹¨ìœ„(RSU) ë³´ìƒì� 받습니다. 회사ëŠ� ê´€ë � 당사ìž� 거래ë‚� 특별í•� í•©ì˜ê°€ ì—†ìŒì� 명시했습니다. 확ì¸ìš� ë³´ë„ìžë£Œ(첨부ìžë£Œ 99.1)ëŠ� 2025ë…� 7ì›� 8ì¼ì— 발표ë˜ì—ˆìŠµë‹ˆë‹�.

ì´ë²ˆ ë³´ê³ ëŠ� 순전íž� 기업 거버넌스 ì—…ë°ì´íЏì´ë©°, ìš´ì˜, 재무 ë˜ëŠ” ì „ëžµì � ì§€ì¹¨ì€ ì œê³µë˜ì§€ 않았습니ë‹�. ë…립ì ì´ê³� ê°ì‚¬ ìžê²©ì� 갖춘 ì´ì‚¬ì� 추가ëŠ� ê°ë…ì� 강화하고 최선ì� 거버넌스 관행과 ì¼ì¹˜í•˜ì§€ë§�, 단기ì ìœ¼ë¡� 재무ì—� 중대í•� ì˜í–¥ì� 미칠 ê°€ëŠ¥ì„±ì€ ë‚®ìŠµë‹ˆë‹¤.

Privia Health Group (PRVA) a déposé un formulaire 8-K (point 5.02) annonçant un changement de gouvernance. À compter du 15 juillet 2025, le conseil d'administration passera de neuf à dix membres et élira Lance Berberian en tant qu'administrateur indépendant de classe III. Il rejoindra également le comité d'audit et répond aux exigences accrues de Nasdaq en matière d'indépendance, de sophistication financière et de maîtrise des connaissances financières.

Dans le cadre du programme de rémunération des administrateurs non salariés de la société, M. Berberian recevra une rémunération annuelle standard en espèces (montant non divulgué) ainsi qu'une attribution d'unités d'actions restreintes d'une valeur de 200 000 $, au prorata de son premier mandat partiel. La société déclare qu'il n'y a aucune transaction avec des parties liées ni d'accords particuliers liés à sa nomination. Un communiqué de presse confirmatif (Exhibit 99.1) a été publié le 8 juillet 2025.

Le dépôt constitue uniquement une mise à jour de la gouvernance d'entreprise ; aucune orientation opérationnelle, financière ou stratégique n'est fournie. Bien que l'ajout d'un administrateur indépendant qualifié en audit devrait renforcer la surveillance et s'aligner sur les meilleures pratiques de gouvernance, cet événement est peu susceptible d'avoir un impact financier significatif à court terme.

Privia Health Group (PRVA) hat ein 8-K Formular (Punkt 5.02) eingereicht, in dem eine Änderung der Unternehmensführung angekündigt wird. Ab dem 15. Juli 2025 wird der Vorstand von neun auf zehn Mitglieder erweitert und Lance Berberian als unabhängiges Direktor der Klasse III gewählt. Er wird außerdem dem Prüfungsausschuss beitreten und erfüllt die verschärften Anforderungen von Nasdaq an Unabhängigkeit, finanzielle Fachkenntnis und Finanzkompetenz.

Im Rahmen des Vergütungsprogramms für nicht angestellte Direktoren erhält Herr Berberian eine standardmäßige jährliche Barvergütung (Höhe nicht veröffentlicht) sowie eine Aktienzuteilung in Form von Restricted Stock Units im Wert von 200.000 $, anteilig für seine erste Teilamtszeit. Das Unternehmen gibt an, dass keine Transaktionen mit verbundenen Parteien oder besondere Absprachen seiner Ernennung zugrunde liegen. Eine bestätigende Pressemitteilung (Anlage 99.1) wurde am 8. Juli 2025 veröffentlicht.

Die Einreichung stellt ausschließlich ein Update der Unternehmensführung dar; es werden keine operativen, finanziellen oder strategischen Prognosen gegeben. Obwohl die Ernennung eines unabhängigen, prüfungserfahrenen Direktors die Aufsicht stärken und den Best-Practice-Governance-Standards entsprechen sollte, wird das Ereignis voraussichtlich keine wesentlichen kurzfristigen finanziellen Auswirkungen haben.

0001759655FALSE00017596552025-07-032025-07-03

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
_________________________
FORM 8-K
_______________________________
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): July 3, 2025
_________________________
Privia Health Group, Inc.
(Exact Name of Registrant as Specified in Its Charter)
_________________________
Delaware
001-4036581-3599420
(State or other jurisdiction of incorporation or organization)
(Commission
File No.)
(I.R.S. Employer Identification No.)
950 N. Glebe Rd.,
Suite 700
Arlington,Virginia22203
(Address of Principal Executive Offices)
(Zip Code)
(571) 366-8850
Registrant's telephone number, including area code

Not Applicable
(Former name, former address and former fiscal year, if changed since last report)

Check the appropriate box below if the form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2 (b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered
Common Stock, $0.01 par value per sharePRVAThe Nasdaq Global Select Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐



Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
The Board of Directors (the “Board”) of Privia Health Group, Inc. (the “Company”) increased the size of the Board from nine to ten directors and elected Lance Berberian to the Board as a Class III director, effective July 15, 2025. The Board also appointed Mr. Berberian as a member of the Audit Committee of the Board effective July 15, 2025.
The Board has determined Mr. Berberian to be independent in accordance with the independence standards of the rules of The Nasdaq Stock Market, and the heightened independence standards, financial sophistication and financial literacy requirements for Audit Committee service. There are no arrangements or understandings between Mr. Berberian and any other persons pursuant to which Mr. Berberian was selected as a director, and there are no transactions in which Mr. Berberian has a direct or indirect material interest requiring disclosure under Item 404(a) of Regulation S-K.
As compensation for his service as a director, Mr. Berberian will receive an annual cash retainer in accordance with the terms and conditions of the Company’s Non-Employee Director Compensation Program (the “Director Compensation Plan”). Consistent with the terms of the Director Compensation Plan, Mr. Berberian will also receive an annual equity grant, pursuant to the 2021 Omnibus Incentive Plan, as amended, of restricted stock units with a grant date fair market value of $200,000. Mr. Berberian will receive an initial grant pro-rated for the number of months that he will serve on the Board through the date of the next annual meeting of stockholders. The terms and conditions of these grants will be governed by an agreement substantially in the form of the Company’s Form of 2021 Omnibus Plan Restricted Stock Unit Award for Non-Employee Directors.
On July 8, 2025, the Company issued a press release announcing the election of Mr. Berberian to the Board. A copy of the Company’s press release is attached hereto as Exhibit 99.1 and incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.
(d) Exhibit:
Exhibit No.Description
99.1
Privia Health Group, Inc. Press Release Dated July 8, 2025
104Cover Page Interactive Data File (formatted as Inline XBRL)



SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

PRIVIA HEALTH GROUP, INC.
Date: July 8, 2025
By:/s/ Parth Mehrotra
Name: Parth Mehrotra
Title: Chief Executive Officer

FAQ

When will Lance Berberian join Privia Health Group's board?

Mr. Berberian will become a director and Audit Committee member on July 15, 2025.

How many directors will Privia Health (PRVA) have after the change?

The board size increases from nine to ten directors.

What compensation will the new PRVA director receive?

He is entitled to the normal cash retainer plus restricted stock units valued at $200,000, pro-rated for his initial term.

Is Lance Berberian considered independent under Nasdaq rules?

Yes. The board determined he satisfies Nasdaq’s independence, audit financial sophistication and literacy standards.

Did Privia Health issue a press release about the appointment?

Yes. A press release dated July 8, 2025 (Exhibit 99.1) announced his election.
Privia Health Group, Inc.

NASDAQ:PRVA

PRVA Rankings

PRVA Latest News

PRVA Stock Data

2.67B
113.74M
10.6%
102.34%
3.44%
Health Information Services
Services-health Services
United States
ARLINGTON